Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), announced results from the open-label Phase 2 SKIPPirr study, ...

Phase 2 trial for lung cancer therapy Rybrevant shows significant reduction in infusion-related reactions with dexamethasone.

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

Dexamethasone can be an effective adjunct to opioid therapy for pain management during the perioperative period in pediatric ...

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

A low-volume local anesthetic with IV dexamethasone in a superior trunk block procedure can reduce the risk of diaphragmatic paresis.

Herbals LLC has issued a nationwide recall of all lots of Vail-Bon Jie Yang Wan  supplement capsules due to the presence of ...